Fenofibrate induces apoptotic injury in cultured human hepatocytes by inhibiting phosphorylation of Akt

Apoptosis

Volumn 10, Issue 2, 2005, Pages 349-358

  Kubota, T ^a   Yano, T ^a   Fujisaki, K ^a   Itoh, Y ^a   Oishi, R ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Akt; Apoptosis; Bcl 2; Caspase; Fenofibrate; Hepatocytes

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 8 HYDROXYARACHIDONIC ACID; BEZAFIBRATE; CASPASE; CIPROFIBRATE; CLOFIBRATE; DNA FRAGMENT; FENOFIBRATE; GEMFIBROZIL; HYDROXY FATTY ACID; INSULIN; MESSENGER RNA; PHOSPHATIDYLSERINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL DAMAGE; CELL MEMBRANE; CELL NUCLEUS; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANNEXIN A5; ANTILIPEMIC AGENTS; APOPTOSIS; CASPASES; CELL LINE; CELL MEMBRANE; CELL NUCLEUS; CELL SURVIVAL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; HEPATOCYTES; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; IMIDAZOLES; IN SITU NICK-END LABELING; INSULIN; MICROSCOPY, FLUORESCENCE; PHOSPHATIDYLSERINES; PHOSPHORYLATION; PPAR ALPHA; PROCETOFEN; PROPIDIUM; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 18044373207     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10495-005-0809-3     Document Type: Article

References (46)

1. Gotto AM. Jr. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998; 82: 22Q-25Q.
2. Robins SJ. PPARalpha ligands and clinical trials: Cardiovascular risk reduction with fibrates. J Cardiovasc Risk 2001; 8: 195-201.
3. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
4. Tugwood JD, Issemann I, Anderson RG, et al. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 1992; 11: 433-439.
5. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983; 25: 57-63.
6. Sharobeem KM, Madden BP, Millner R, et al. Acute renal failure after cardiopulmonary bypass: A possible association with drugs of the fibrate group. J Cardiovasc Pharmacol Ther 2000; 5: 33-39.
7. Lelouch S, Pelletier G, Sinico M, Ducreux M, Etienne JP. Fenofibrate-induced acute hepatitis with pseudo-cholangitis. Gastroenterol Clin Biol 1992; 16: 597-599.
8. Najib J. Fenofibrate in the treatment of dyslipidemia: A review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther 2002; 24: 2022-2050.
9. Muscari A, Puddu GM, Puddu P. Lipid-lowering drugs: Are adverse effects predictable and reversible? Cardiology 2002; 97: 115-121.
10. Sasaki J, Yamamoto K, Ageta M. Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: A randomized, double-blind, placebo-controlled, multicenter, crossover study. Clin Ther 2002; 24: 1614-1626.
11. Krempf M, Rohmer V, Farnier M. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia. Diabetes Metab 2000; 26: 184-191.
12. Goll V, Viollon-Abadie C, Nicod L, Richert L. Peroxisome proliferators induce apoptosis and decrease DNA synthesis in hepatoma cell lines. Hum Exp Toxicol 2000; 19: 193-202.
13. Canuto RA, Muzio G, Bonelli G, et al. Peroxisome proliferators induce apoptosis in hepatoma cells. Cancer Detect Prev 1998; 22: 357-366.
14. Perrone CE, Shao L, Williams GM. Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol Appl Pharmacol 1998; 150: 277-286.
15. Jiao HL, Zhao BL. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol Appl Pharmacol 2002; 185: 172-179.
16. Maiguma T, Fujisaki K, Itoh Y, et al. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn-Schmiedebergs Arch Pharmacol 2003; 67: 289-296.
17. Panaretakis T, Shabalina IG, Grander D, Shoshan MC, DePierre JW. Reactive oxygen species and mitochondria mediate the induction of apoptosis in human hepatoma HepG2 cells by the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid. Toxicol Appl Pharmacol 2001; 173: 56-64.
18. Atarod EB, Kehrer JP. Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines. Free Radic Biol Med 2004; 37: 36-47.
19. Goetze S, Eilers F, Bungenstock A, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 2002; 293: 1431-1437.
20. Kandel ES, Hay N. The regulation and activities of the multi-functional serine/threonine kinase Akt/PKB. Exp Cell Res 1999; 253: 210-229.
21. Goswami R, Dawson SA, Dawson G. Multiple polyphosphoinositide pathways regulate apoptotic signalling in a dorsal root ganglion derived cell line. J Neurosci Res 2000; 59: 136-144.
22. Kubota T, Fujisaki K, Itoh Y, et al. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol 2004; 67: 2175-2186.
23. Shino Y, Itoh Y, Kubota T, et al. Role of poly(ADP-ribose) polymerase in cisplatin-induced injury in LLC-PK1 cells. Free Rad Biol Med 2003; 35: 966-977.
24. Lee EH, Wan XH, Song J, et al. Lens epithelial cell death and reduction of anti-apoptotic protein Bcl-2 in human anterior polar cataracts. Mol Vision 2002; 8: 235-240.
25. Fadok VA, Voelker DR, Campbell PA et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148: 2207-2216.
26. van Engeland M, Ramaekers FC, Schutte B, Reutelingsperger CP. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 1996; 24: 131-139.
27. Zhu H, Fearnhead HO, Cohen GM. An ICE-like protease is a common mediator of apoptosis induced by diverse stimuli in human monocytic THP.1 cells. FEBS Lett 1995; 374: 303-308.
28. Muga SJ, Thuillier P, Pavone A, et al. 8S-lipoxygenase products activate peroxisome proliferator-activated receptor alpha and induce differentiation in murine keratinocytes. Cell Growth Differ 2000; 11: 447-454.
29. Yu K, Bayona W, Kallen CB, et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995; 270: 23975-23983.
30. Varet J, Vincent L, Mirshahi P, et al. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 2003; 60: 810-819.
31. Ishiyama M, Miyazono Y, Sasamoto K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 1997; 44: 1299-1305.
32. Yeh CJ, His BL, Faulk WP. Propidium iodide as a nuclear marker in immunofluorescence. II. Use with cellular identification and viability studies. J Immunol Methods 1981; 43: 269-275.
33. Hall PA. Assessing apoptosis: A critical survey. Endocr Relat Cancer 1999; 6: 3-8.
34. Salvesen GS, Dixit VM. Caspases: Intracellular signaling by proteolysis. Cell 1997; 91: 443-446.
35. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998; 281: 1312-1316.
36. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1b-converting enzyme-like proteases. Proc Natl Acad Sci USA 1996; 93: 14559-14563.
37. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 1997; 3: 614-620.
38. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998; 17: 3878-3885.
39. Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase, Akt. J Am Chem Soc 2003; 125: 1144-1145.
40. Meuillet EJ, Mahadevan D, Vankayalapati H, et al. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Mol Cancer Ther 2003; 2: 389-399.
41. +/taurocholate cotransport and Ntcp translocation. J Biol Chem 2002; 277: 28578-28583.
42. Lali FV, Hunt AE, Turner SJ, Foxwell BM. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 2000; 275: 7395-7402.
43. Pugazhenthi S, Miller E, Sable C, et al. Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein. J Biol Chem 1999; 274: 27529-27535.
44. Pugazhenthi S, Nesterova A, Sable C, et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 2000; 275: 10761-10766.
45. Harvengt C, Desager JP. Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers. Eur J Clin Pharmacol 1980a; 17: 459-463.
46. Harvengt C, Desager JP. Pharmacokinetics of fenofibrate in man. Nouv Presse Med 1980b; 9: 3725-3727.